New Study Shows Ivermectin Reduces COVID Hospitalizations and Mortality

New Study Shows Ivermectin Reduces COVID Hospitalizations and Mortality

A recently published study shows ivermectin, a popular drug used to treat parasites — and used off-label by many for the prevention and treatment of COVID — worked well as a prophylactic against the SARS-CoV-2 virus that causes COVID.

Yet, the mainstream media has ignored the findings of the peer-reviewed study in its continued pursuit of vaccines and expensive pharmaceutical drugs that do not work.

The study, called Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching, was published on Jan. 15 in the journal Cureus.

The objective of the study was to evaluate the impact of regular ivermectin use on subsequent COVID infection and mortality rates.

The Brazilian city of Itajaí launched a program that provided ivermectin to anyone who wanted it over the five-month period in 2020. Scientists found the program, which included over 100,000 participants, was linked to a 44% drop in COVID cases.

Approximately 3.7% of ivermectin users contracted the illness during the trial period, compared to 6.6% of residents who didn’t take the drug. Those who took ivermectin also saw a statistically significant decrease in hospitalizations and mortality.

“Ivermectin MUST be considered as an option, particularly during outbreaks,” Dr. Flavio Cadegiani, one of the study’s authors and a founding member of Front Line COVID-19 Critical Care Alliance (FLCCC) said when asked about the study.

Dr. Pierre Kory, president of FLCCC said the lack of reporting on a peer-reviewed study highlights how some scientific developments are ignored by many media outlets and scientists.

“You would think this would lead major headlines everywhere. And yet, nothing. And this is not new, this censorship of this highly effective science and evidence around repurposed drugs. The censoring of it, it’s not new, it’s just getting more and more absurd. And it has to stop,” he said.

According to the study, ivermectin has been demonstrated to have extensive anti-parasitic actions, anti-viral, anti-bacterial and anti-protozoan properties — and has long been proposed for use as a repurpose viral agent.

“Indeed, antiviral effects of ivermectin have been reported against both RNA and DNA types of viruses, including HIV-1, yellow fever, Japanese encephalitis, tick-borne encephalitis, West Nile, Zika, dengue fever, chikungunya, Venezuelan equine encephalitis and the pseudorabies virus, as well as functioning in regulation of proteins involved in antiviral responses.”

Cadegiani said to date, this is the best observational study on COVID, with a “power almost equivalent to a huge randomized clinical trial.”